Hollow Temples

Temple hollowing is typically driven by one or more of four factors: bone resorption in the sphenoid and temporal bones, atrophy of the deep and superficial temporal fat pads, temporalis muscle atrophy (especially with significant weight loss or systemic illness), and genetic predisposition to a narrow bitemporal width or flat temporal bone. Most patients have two or more drivers contributing simultaneously, which is why a consultation-based driver assessment matters before selecting a product.

It depends on the driver. Age-related bone resorption and fat-pad atrophy usually become visible in the mid-30s to 40s. Genetics-driven hollowing can appear as early as the 20s. Significant weight loss or caloric restriction can accelerate fat-pad and muscle atrophy by decades — patients in their 20s or 30s who have experienced rapid weight loss sometimes present with hollowing that would typically not appear until 50. There is no single age threshold; the driver determines the timeline.

It depends on the severity of hollowing and the dominant driver. For mild to moderate hollowing, Restylane Lyft or RHA 4 (HA filler) provides an immediate, reversible result and is first-line for most patients. For moderate to severe hollowing where longevity and tissue rebuilding are priorities, Sculptra is the preferred option — it builds collagen over a series of sessions and lasts 2+ years. Radiesse is a strong middle-ground option when both immediate correction and progressive collagen induction are wanted. At Desert Bloom, HA options are Restylane and RHA only — not Juvederm Voluma.

In the hands of an anatomically trained provider, yes. Temple filler has a strong safety record when performed with correct technique and product selection. The risk profile increases significantly with less experienced injectors — the frontal branch of the facial nerve and the deep temporal artery both run in this zone, and wrong-plane injection can cause permanent motor nerve damage or vascular complications. Choosing a provider specifically experienced with this anatomy — not just generally certified in filler — is the primary safety variable.

HA filler (Restylane Lyft or RHA 4): 12–18 months typical, with variation by individual metabolism, exercise level, and injection volume. Sculptra: 2 years or longer after completing the full series; results build gradually and last well beyond HA. Radiesse: 12–18 months. PRP Biofiller (Velora): used as an adjunct — the tissue-quality improvement component varies by patient. Most patients schedule HA temple filler maintenance annually; Sculptra patients typically need touch-up sessions every 2 years.

Yes — and for moderate to severe hollowing, it is often the best standalone option. Because Sculptra builds collagen progressively, it does not provide an immediate correction visible the same day. Patients choose Sculptra when they have the time for a series (3–4 sessions over 3–4 months) and prefer a result that builds naturally and lasts longer than HA filler. Some patients combine Sculptra with a small amount of HA filler in the first session to see an immediate correction while the collagen-building effect develops.

Yes — injectable treatments can restore temple volume non-surgically and without any surgical risk, recovery time, or scarring. HA filler results are fully reversible with hyaluronidase. Bio-stimulators (Sculptra, Radiesse) are not reversible but fade naturally over 1–2+ years. In cases of severe temporalis muscle atrophy from extreme weight loss, non-surgical correction has limits — fillers can improve the appearance significantly but may not fully reproduce the volume that was lost from a structurally atrophied muscle. Dr. Borakowski will give you an honest assessment of realistic outcomes at the consultation.